Complacency in GERD an Imminent Disaster
DOI:
https://doi.org/10.53685/jshmdc.v4i1.159Abstract
Gastroesophageal reflux disease is one of the most common gastrointestinal disorders which is mainly characterized by problems with esophageal peristalsis, which is responsible for propelling food from the esophagus into the stomach or dysfunctional or weaker lower esophageal sphincter, which prevents the reflux to stomach contents.Typical symptoms involve heartburn, regurgitation of food, a sore taste in the mouth, and sometimes atypical symptoms like chest pain, signs of dental erosion and even breathlessness at night. There is also a trend of testing for helicobacter pylori in GERD patients which is absolutely not recommended at all as there is no evidence that eradication therapy will ease the symptoms.Instead, it has contributed to widespread antimicrobial resistance with physicians using them, which is otherwise a futile exercise. There is no need to try different proton pump inhibitors for a long time when there is no improvement in symptoms.The physicians in general practice should rather be generous in referring such patients on time to gastroenterology experts, as the treatment needs to be multidisciplinary and one should not be silent on sinister signs and symptoms if they are present. Endoscopy is already a safer option to screen such patients, which will suffice for the reassurance of the patients.
References
Mousa H, Hassan M. Gastroesophageal reflux disease. Pediatr Clin North Am. 2017; 64(3): 487–505. doi:10.1016/j.pcl.2017.01. 003. DOI: https://doi.org/10.1016/j.pcl.2017.01.003
Choe JW, Joo MK, Kim HJ, Lee BJ, Kim JH, Yeon JE, et al. Foods inducing typical gastroesophageal reflux disease symptoms in Korea. J Neurogastroenterol Motil. 2017; 23(3): 363–369. doi:10.5056/jnm16122 DOI: https://doi.org/10.5056/jnm16122
Azzam RS. Are the persistent symptoms to proton pump inhibitor therapy due to refractory gastroesophageal reflux disease or to other disorders? Arq Gastroenterol. 2018; 55(Suppl-1): 85–91. doi:10.1590/S0004-280 3.201800000-48. DOI: https://doi.org/10.1590/s0004-2803.201800000-48
Gyawali CP, Fass R. Management of gastroesophageal reflux disease. Gastroenterology. 2018; 154(2): 302–318. doi :10.1053/j.gastro.2017.07.049. DOI: https://doi.org/10.1053/j.gastro.2017.07.049
Chiang HH, Wu DC, Hsu PI, Kuo CH, Tai WC, Yang SC, et al. Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: A prospective randomized trial. Drug Des Devel Ther. 2019; 13: 1347–1356. doi:10.214 7/DDD T.S193559. DOI: https://doi.org/10.2147/DDDT.S193559
Liang CM, Kuo M Te, Hsu PI, Kuo CH, Tai WC, Yang SC, et al. First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease. World J Gastroenterol. 2017; 23(47): 8395-8404. doi:10.3748/wjg.v23.i47. 8395. DOI: https://doi.org/10.3748/wjg.v23.i47.8395
Alexander SM, Retnakumar RJ, Chouhan D, Devi TNB, Dharmaseelan S, Devadas K, et al. Helicobacter pylori in Human Stomach: The Inconsistencies in Clinical Outcomes and the Probable Causes. Front Microbiol. 2021; 12: 713955. doi:10.3389/fmicb.2021.71 3955. DOI: https://doi.org/10.3389/fmicb.2021.713955
Song JH, Kim YS, Choi SY, Yang SY. Association between gastroesophageal reflux disease and coronary atherosclerosis. PLoS One. 2022; 17(5): e0267053. doi:10.137 1/journal.pone.0267053. DOI: https://doi.org/10.1371/journal.pone.0267053
Kalapala R, Karyampudi A, Nabi Z, Darisetty S, Jagtap N, Ramchandani M, et al. Endoscopic full-thickness plication for the treatment of PPI-dependent GERD: Results from a randomised, sham-controlled trial. Gut. 2022; 71(4): 686–694. doi:10.1136 /gutjnl-2020-321811. DOI: https://doi.org/10.1136/gutjnl-2020-321811
Sharma P, Shaheen NJ, Katzka D, Bergman JJGHM. aga clinical practice update on endoscopic treatment of barrett's esophagus with dysplasia and/or early cancer: Expert Review.Gastroenterology.2020; 158(3):760-769. doi:10.1053/j.gas tro.2019. 09.051. DOI: https://doi.org/10.1053/j.gastro.2019.09.051
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Jibran Umar Ayub Khan, Azhar Zahir Shah , Ayesha Qaisar
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
-
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
-
Non Commercial — You may not use the material for commercial purposes.
-
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
This work is licensed under a 
